Dr Jansen trained in internal medicine at Academic Hospital St Radboud, Nijmegen, and Rijnstate Hospital, Arnhem – earning his PhD at the latter. In 1995 he began training in rheumatology and subsequently became a rheumatologist staff member in the Medical Centre Leeuwarden, carrying out research and co-authoring publications on biologicals in rheumatoid arthritis (RA) and treatment modalities in gout. Dr Jansen was previously a staff member in the department of rheumatology at the UMCN St Radboud, and in 2014 became the medical leader in rheumatology at VieCuri MC. Dr Jansen is a member of the Dutch Society of Rheumatology. During his tenure as a board member, he participated in inter/national consensus meetings, and co-authored the consumer quality index in RA, national guidelines for the diagnosis and treatment of RA, a national set of quality indicators in RA, and the national guideline, “Appropriate use of biologicals in rheumatic diseases”. Dr Jansen was the principal investigator of the TNF-inhibitor (TNFi) stop study (doi: 10.1002/art.39626), the Dutch POET (Potential Optimalisation of Expediency of TNF-i) and the POET-ultrasonography (US) study. Other gout research includes the Study for Updated Gout Classification Criteria (SUGAR) and the updated European League Against Rheumatism (EULAR) gout guideline. Dr Jansen has also participated in several advisory boards on optimal pharmacotherapy in RA, psoriatic arthritis and gouty arthritis.